Human monoclonal antibodies (mAbs)--highly specific, identical, infection-fighting proteins produced in large quantities in the lab in cell lines that are derived from a single cell--against influenza ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Prolific Machines, a biotechnology innovator harnessing light to deliver unprecedented cellular control, has received a grant from the Bill & Melinda Gates ...

Monoclonal antibody (mAb)-based therapeutics are emerging as one of the fastest-growing categories of drugs being developed today. In fact, according to a recent analysis, 1 the market for mAbs has ...

Monoclonal antibodies (mAbs) make up one of the most important classes of advanced biotherapies. To find out about the current challenges and advances in the production of mAbs, GEN talked with Lukas ...

The development of monoclonal antibodies—human immune proteins that can provide rapid, passive protection against some infectious diseases—is progressing quickly and holds great promise for expanding ...

Monoclonal antibodies (mAbs) can achieve unparalleled affinity and specificity for a wide range of biomolecules, making the reagents critical to both basic and clinical research. The vast majority of ...

Human monoclonal antibodies against influenza can be rapidly produced in the lab, according to a new report. Using cells drawn from volunteers inoculated with seasonal influenza vaccine, the ...